BlinkLab Limited (ASX:BB1): Are Analysts Optimistic?

We feel now is a pretty good time to analyse BlinkLab Limited's (ASX:BB1) business as it appears the company may be on the cusp of a considerable accomplishment. BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-based neurobehavioural testing. The AU$89m market-cap company announced a latest loss of AU$7.2m on 30 June 2026 for its most recent financial year result. The most pressing concern for investors is BlinkLab's path to profitability – when will it breakeven? In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

BlinkLab is bordering on breakeven, according to the 3 Australian Healthcare Services analysts. They anticipate the company to incur a final loss in 2028, before generating positive profits of AU$10m in 2029. So, the company is predicted to breakeven approximately 3 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2029? Working backwards from analyst estimates, it turns out that they expect the company to grow 60% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

We're not going to go through company-specific developments for BlinkLab given that this is a high-level summary, however, keep in mind that typically healthcare tech companies, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

See our latest analysis for BlinkLab

Before we wrap up, there’s one aspect worth mentioning. BlinkLab currently has no debt on its balance sheet, which is quite unusual for a cash-burning healthcare tech company, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on BlinkLab, so if you are interested in understanding the company at a deeper level, take a look at BlinkLab's company page on Simply Wall St. We've also put together a list of key aspects you should look at:

1. Historical Track Record: What has BlinkLab's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on BlinkLab's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.